Blog
RSS FeedPosted by Michael Wonder on 22 Mar 2019
PBAC Report - Options for listing PD-(L)1 checkpoint inhibitors for multiple cancer indications on the PBS
22 March 2019 - The PBAC Report to the Minister for Health on “Options for listing PD(L)-1 checkpoint inhibitors for multiple ...
Posted by Michael Wonder on 19 Mar 2019
Private health insurance costs the biggest household spending concern, survey finds
19 March 2019 - Private health insurance costs have overtaken electricity bills as the biggest household spending worry, according to ...
Posted by Michael Wonder on 18 Mar 2019
Three new drugs added to PBS to ease cost pain
19 March 2019 - Three new treatments to help save or prolong the lives of thousands of Australians suffering from ...
Posted by Michael Wonder on 18 Mar 2019
New early breast cancer drug to reduce risk of recurrence or death approved for Australian women
18 March 2019 - Nerlynx (neratinib) now approved by the Therapeutic Goods Administration for Australian women. ...
Posted by Michael Wonder on 18 Mar 2019
Brexit - implications for therapeutic goods in Australia
18 March 2019 - In the event of a 'no deal' exit of the United Kingdom from the European Union, ...
Posted by Michael Wonder on 17 Mar 2019
What 1 April 2019 private health insurance changes mean for you
17 March 2019 - When the calendar flips to April 1 this year, many private health insurance customers will need ...
Posted by Michael Wonder on 17 Mar 2019
'Have you got insurance?': the US style question finding its way to Australian hospitals
16 March 2019 - “Have you got insurance?” It is the first question faced by any patient walking into a ...
Posted by Michael Wonder on 15 Mar 2019
PBAC Public Summary Documents - November 2018 meeting (rejections and deferrals)
15 March 2019 - The Public Summary Documents (first time rejections and deferrals) from the November 2018 PBAC meeting are now ...
Posted by Michael Wonder on 12 Mar 2019
Vertex receives approval for Symdeko (tezacaftor/ivacaftor and ivacaftor) in Australia, to treat the underlying cause of cystic fibrosis in people aged 12 and older with certain CFTR gene mutations
12 March 2019 - A new treatment option for patients with two copies of the F508del mutation, the most common mutation ...
Posted by Michael Wonder on 11 Mar 2019
Vulnerable and shocked: patients targeted by hospital revenue push
11 March 2019 - A new mum hours out of surgery and suffering from blood loss was badgered by the ...
Posted by Michael Wonder on 11 Mar 2019
Health funds warn they will be on life support without premium relief
10 March 2019 - Health funds are warning membership rates will plummet to 30% and some insurers will go out ...
Posted by Michael Wonder on 11 Mar 2019
Health insurers battle public hospitals over $1billion a year cash grab
11 March 2019 - Hospital patients are getting caught in the middle of a battle between public hospitals and private ...
Posted by Michael Wonder on 08 Mar 2019
Direct-acting anti-virals for hepatitis C - outcome statement
8 March 2019 - The outcome statement for the direct-acting anti-virals for hepatitis C stakeholder meeting held on 13 December 2018 ...
Posted by Michael Wonder on 08 Mar 2019
Continued support for Australia’s community pharmacies
8 March 2019 - The Australian Government has announced key measures to support the delivery of medicines and important patient services ...
Posted by Michael Wonder on 05 Mar 2019
Can Netflix show Americans how to cut the cost of drugs?
5 March 2019 - Australia seems to have found a way to entice Big Pharma into making essential new medicines affordable. ...